Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin + Metformin Initial Combination in T2DM
NCT01719003Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Oct 2012; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01719003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01719003.